Entero Therapeutics is advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its three proprietary technologies – latiglutenase, a potentially first-in-class, Phase 3, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease; Phase 2 capeserod, a selective 5-HT4 receptor partial agonist being developed for multiple gastrointestinal indications; and adrulipase, a Phase 2 a recombinant lipase designed to enable the digestion of fats and other nutrients in patients with exocrine pancreatic insufficiency.

Entero Therapeutics is developing these technologies for a host of GI diseases where there are significant unmet clinical needs and limited therapeutic options, resulting in painful, life threatening and discomforting consequences for patients. Our goal is to help protect the health and restore quality of life for the millions of people afflicted.